Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer

British Journal of Cancer

Volumn 77, Issue 11, 1998, Pages 1870-1874

  Obermair, A ^a   Tempfer, C ^a   Hefler, L ^a   Preyer, O ^a   Kaider, A ^b   Zeillinger, R ^a   Leodolter, S ^a   Kainz, C ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CA 125; Differential diagnosis; Early diagnosis; Ovarian cancer; Vascular endothelial growth factor

Indexed keywords

CA 125 ANTIGEN; VASCULOTROPIN;

ADNEXA DISEASE; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; OVARY CYST; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 0031778020     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.311     Document Type: Article

References (31)

1. Bancher-Todesca D, Obermair A, Bilgi S, Kohlberger P, Kainz C, Breitenecker G, Leodolter S and Gitsch G (1997) Angiogenesis in vulvar intraepithelial neoplasia. Gynecol Oncol 64: 496-500
2. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR and Smith SK (1995) Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506-516
3. Campbell MJ and Machin D (1995) Medical Statistics - a Commonsense Approach. John Wiley & Sons: Chichester
4. Christenson LK and Stouffer RL (1996) Proliferation of microvascular endothelial cells in the primate corpus luteum during the menstrual cycle and simulated early pregnancy. Endocrinology 137: 367-374
5. Ferrara N and Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-859
6. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27-31
7. Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R and Facchini V (1996) Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 60: 197-202
8. Gordon JD, Mesiano S, Zaloudek CJ and Jaffe RB (1996) Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 81: 353-359
9. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF and Brown LF (1995) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87: 1237-1245
10. Hosmer DJ and Lemeshow S (1989) Applied Logistic Regression. Wiley: New York
11. International Federation of Gynecologists and Obstetricians (FIGO) (1987) Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263-264
12. Jacobs I and Bast RC (1989) The CA 125 tumor-associated antigen: a review of the literature. Hum Reprod 4: 1-12
13. Jacobs IJ, Skates S, Davies AP, Woolas AP, Jeyerajah A, Weidemann P, Sibley K and Oram DH (1996) Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. Br Med J 313: 1355-1358
14. Kamat BR, Brown LF, Manseau EJ, Senger DR and Dvorak HF (1995) Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Am J Pathol 146: 157-165
15. Ke-Lin, Qu-Hong, Nagy JA, Eckelhoefer IA, Masse EM, Dvorak AM and Dvorak HF (1996) Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Eur J Cancer 32A: 2467-2473
16. Klauber N, Rohan RM, Flynn E and D'Amato RJ (1997) Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nature Med 3: 443-446
17. Kondo S, Asano M, Matsuo K, Ohmori I and Suzuki H (1994) Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1221: 211-214
18. Markowska J, Kopczynski Z, Szewierski Z, Markowski M and Niecewicz R (1994) The value of estimating CA 125 in fluids from benign or malignant cysts, in the exudate and blood serum in women with ovarian cancer. Eur J Gynaecol Oncol 15: 29-32
19. Mattern J, Stammler G, Koomagi R, Wallwiener D, Kaufmann M and Volm M (1997) Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Anticancer Res 17: 621-624
20. Melnyk O, Shuman MA and Kim KJ (1996) Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 56: 921-924
21. Neufeld G, Cohen T, Gitay-Goren H, Poltorak Z, Tessler S, Sharon R, Gengrinovitch S and Levi BZ (1996) Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metas Rev 15: 153-158
22. Obermair A, Bancher-Todesca D, Bilgi S, Kaider A, Kohlberger P, Müllauer-Ertl S, Leodolter S and Gitsch G (1997) Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithclial neoplasia. J Natl Cancer Inst 89: 1212-1217
23. Oram DH and Jeyarajah AR (1994) The role of ultrasound and tumor markers in the early detection of ovarian cancer. Br J Obstet Gynaecol 101: 939-945
24. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS and Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985
25. Serov SF, Scully RE and Sarbin LH (1973) International Histological Classification of Tumors. WHO: Geneva
26. Soker S, Svahn S and Neufeld G (1993) Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. J Biol Chem 268: 7685-7691
27. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S and Nose T (1996) Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56: 2185-2190
28. Terman BI and Dougher-Vermazen M (1996) Biological properties of VEGF/VPF receptors. Cancer Metast Rev 15: 159-163
29. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT, Clarke-Pearson DL, Rodriguez G, Oram DH and Bast RC Jr (1995) Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59: 111-116
30. Yeo KT, Sioussat TM, Faix JD, Senger DR and Yeo TK (1992) Development of time-resolved immunofluorometric assay of vascular permeability factor. Clin Chem 38: 71-75
31. Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF and Yeo TK (1993) Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 53: 2912-2918